Status:
COMPLETED
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study
Lead Sponsor:
University Hospital of Mont-Godinne
Collaborating Sponsors:
GlaxoSmithKline
Université Catholique de Louvain
Conditions:
Epilepsy
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
The objective of this study is to characterize the effects of a single-dose of retigabine on cortical excitability in healthy subjects, as quantified by means of TMS.
Detailed Description
Epilepsy is a disorder of brain excitability. Antiepileptic drugs (AEDs) modulate this excitability and transcranial magnetic stimulation (TMS) imposed itself as one of the best noninvasive methods to...
Eligibility Criteria
Inclusion
- age 18-50 years
- being "healthy"
- willing to participate and able to understand study and provide informed consent
Exclusion
- intake of psycho-active drugs (AEDS, antidepressants, benzodiazepines, neuroleptics, hypnotics, ...)
- alcohol or drug abuse
- antecedent of seizure
- contra-indication to TMS (metal in the head, skull fracture)
- contra-indication to retigabine.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01823159
Start Date
April 1 2013
End Date
January 1 2014
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Mont-Godinne
Yvoir, Namur, Belgium, 5350